REVONTO (dantrolene sodium)
REVONTO is indicated for the treatment of Malignant Hyperthermia.
Details
- Status
- Prescription
- First Approved
- 2007-07-24
- Routes
- INJECTION
- Dosage Forms
- INJECTABLE
REVONTO Approval History
What REVONTO Treats
1 indicationsREVONTO is approved for 1 conditions since its original approval in 2007. These indications span multiple therapeutic areas including oncology, immunology, and more.
- Malignant Hyperthermia
Drugs Similar to REVONTO
FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.
Clinical Trial Registry
1 trials| Trial | Sponsor ID | Phase | Status | Title |
|---|---|---|---|---|
| NCT02829268 results posted | 201607006 R21DK113487 | Ph 1, Ph 2 | completed | A Clinical Trial of Dantrolene Sodium in Pediatric and Adult Patients With Wolfram Syndrome |
Active Pipeline
Ongoing clinical trials by development phase
Key Completed Trials
Completed studies with published results, ranked by significance
Trial Timeline
Full development history with FDA approval milestones
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
REVONTO FDA Label Details
Indications & Usage
REVONTO is indicated for the treatment of Malignant Hyperthermia.
Track REVONTO with TheraRadar Pro
Watchlist alerts, full database access, CSV exports across 14,000+ drugs.
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.